PMID- 25266124
OWN - NLM
STAT- MEDLINE
DCOM- 20160607
LR  - 20211021
IS  - 1476-5578 (Electronic)
IS  - 1359-4184 (Linking)
VI  - 20
IP  - 9
DP  - 2015 Sep
TI  - Peripheral brain-derived neurotrophic factor in schizophrenia and the role of 
      antipsychotics: meta-analysis and implications.
PG  - 1108-19
LID - 10.1038/mp.2014.117 [doi]
AB  - It has been postulated that schizophrenia (SZ) is related to a lower expression 
      of brain-derived neurotrophic factor (BDNF). In the past few years, an increasing 
      number of divergent clinical studies assessing BDNF in serum and plasma have been 
      published. It is now possible to verify the relationship between BDNF levels and 
      severity of symptoms in SZ as well as the effects of antipsychotic drugs on BDNF 
      using meta-analysis. The aims of this study were to verify if peripheral BDNF is 
      decreased in SZ, whether its levels are correlated with positive and negative 
      symptomatology and if BDNF levels change after antipsychotic treatment. This 
      report consists of two distinct meta-analyses of peripheral BDNF in SZ including 
      a total of 41 studies and more than 7000 participants: (1) peripheral BDNF levels 
      in serum and plasma were moderately reduced in SZ compared with controls. 
      Notably, this decrease was accentuated with the disease duration. However, the 
      extent of peripheral BDNF level decrease did not correlate with the severity of 
      positive and negative symptoms. (2) In plasma, but not serum, peripheral BDNF 
      levels are consistently increased after antipsychotic treatment irrespective of 
      the patient's response to medication. In conclusion, there is compelling evidence 
      that there are decreased levels of peripheral BDNF in SZ, in parallel to 
      previously described reduced cerebral BDNF expression. It remains unclear whether 
      these systemic changes are causally related to the development of SZ or if they 
      are merely a pathologic epiphenomenon.
FAU - Fernandes, B S
AU  - Fernandes BS
AD  - Laboratory of Calcium Binding Proteins in the Central Nervous System, Department 
      of Biochemistry, Federal University of Rio Grande do Sul, Porto Alegre, Brazil.
AD  - Post-graduate Program in Biological Sciences: Biochemistry, Federal University of 
      Rio Grande do Sul, Porto Alegre, Brazil.
FAU - Steiner, J
AU  - Steiner J
AD  - Department of Psychiatry, University of Magdeburg, Magdeburg, Germany.
FAU - Berk, M
AU  - Berk M
AD  - IMPACT Strategic Research Centre, Deakin University, School of Medicine, Barwon 
      Health, Geelong, VIC, Australia.
AD  - Florey Institute for Neuroscience and Mental Health, Department of Psychiatry and 
      Orygen Research Centre, University of Melbourne, Parkville, VIC, Australia.
FAU - Molendijk, M L
AU  - Molendijk ML
AD  - Department of Clinical Psychology, Institute of Psychology, Leiden University, 
      Leiden, The Netherlands.
AD  - Leiden Institute for Brain and Cognition, Leiden University Medical Center, 
      Leiden, The Netherlands.
FAU - Gonzalez-Pinto, A
AU  - Gonzalez-Pinto A
AD  - University of the Basque Country, Biomedical Research Center in Mental HealthNet 
      (CIBERSAM), Department of Neurosciences, University of the Basque Country, 
      Vitoria, Spain.
FAU - Turck, C W
AU  - Turck CW
AD  - Max Planck Institute of Psychiatry, Munich, Germany.
FAU - Nardin, P
AU  - Nardin P
AD  - Laboratory of Calcium Binding Proteins in the Central Nervous System, Department 
      of Biochemistry, Federal University of Rio Grande do Sul, Porto Alegre, Brazil.
AD  - Post-graduate Program in Biological Sciences: Biochemistry, Federal University of 
      Rio Grande do Sul, Porto Alegre, Brazil.
FAU - Goncalves, C-A
AU  - Goncalves CA
AD  - Laboratory of Calcium Binding Proteins in the Central Nervous System, Department 
      of Biochemistry, Federal University of Rio Grande do Sul, Porto Alegre, Brazil.
AD  - Post-graduate Program in Biological Sciences: Biochemistry, Federal University of 
      Rio Grande do Sul, Porto Alegre, Brazil.
LA  - eng
PT  - Journal Article
PT  - Meta-Analysis
PT  - Research Support, Non-U.S. Gov't
DEP - 20140930
PL  - England
TA  - Mol Psychiatry
JT  - Molecular psychiatry
JID - 9607835
RN  - 0 (Antipsychotic Agents)
RN  - 0 (Biomarkers)
RN  - 0 (Brain-Derived Neurotrophic Factor)
SB  - IM
MH  - Adult
MH  - Antipsychotic Agents/*therapeutic use
MH  - Biomarkers/blood
MH  - Brain-Derived Neurotrophic Factor/*blood
MH  - Case-Control Studies
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Schizophrenia/*blood/*drug therapy
MH  - Young Adult
EDAT- 2014/10/01 06:00
MHDA- 2016/06/09 06:00
CRDT- 2014/10/01 06:00
PHST- 2014/05/14 00:00 [received]
PHST- 2014/08/06 00:00 [revised]
PHST- 2014/08/21 00:00 [accepted]
PHST- 2014/10/01 06:00 [entrez]
PHST- 2014/10/01 06:00 [pubmed]
PHST- 2016/06/09 06:00 [medline]
AID - mp2014117 [pii]
AID - 10.1038/mp.2014.117 [doi]
PST - ppublish
SO  - Mol Psychiatry. 2015 Sep;20(9):1108-19. doi: 10.1038/mp.2014.117. Epub 2014 Sep 
      30.